Orpheus | Search

Trials

18 participants · First posted Jan 18, 2020

Completed

NCT05583955

A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)

75 participants · First posted Oct 18, 2022

Recruiting

NCT07328152

CoMbination of Data From European Cohorts as Part of the European MORPHEUS Project [HORIZON-HLTH-2022-11-01] - "MC-MORPHEUS".

20,000 participants · First posted Jan 9, 2026

Drugs

View all 5 →

Biotech

Approved

Avelumab(Bavencio)

Conditions: Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer +2 more

Biotech

Approved

Ipilimumab(Yervoy)

Conditions: Cutaneous Melanoma, Hepatocellular Carcinoma +10 more

Rx

Biotech

Approved

Atezolizumab(Tecentriq)

Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma +11 more

Rx

Organizations

Orpheris, Inc.

United States

Alpheus Medical, Inc.

United States

News

View all 11 →

2 years ago

Advancements in Penile Cancer Treatment: ESMO 2024 Highlights Neoadjuvant Strategies and Immunotherapy

last month

Multimodal AI in Surgical Oncology Shows Promise but Lacks Prospective Evidence, Review Finds

last year

Trials

Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)

A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)

CoMbination of Data From European Cohorts as Part of the European MORPHEUS Project [HORIZON-HLTH-2022-11-01] - "MC-MORPHEUS".

Drugs

Avelumab(Bavencio)

Ipilimumab(Yervoy)

Atezolizumab(Tecentriq)

Organizations

Orpheris, Inc.

Alpheus Medical, Inc.

News

Advancements in Penile Cancer Treatment: ESMO 2024 Highlights Neoadjuvant Strategies and Immunotherapy

Multimodal AI in Surgical Oncology Shows Promise but Lacks Prospective Evidence, Review Finds

Alpheus Medical's Sonodynamic Therapy Shows Promise in Recurrent High-Grade Gliomas